Literature DB >> 25781442

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.

Hongmei Nan1, Carolyn M Hutter2, Yi Lin3, Eric J Jacobs4, Cornelia M Ulrich5, Emily White6, John A Baron7, Sonja I Berndt8, Hermann Brenner9, Katja Butterbach10, Bette J Caan11, Peter T Campbell4, Christopher S Carlson3, Graham Casey12, Jenny Chang-Claude13, Stephen J Chanock8, Michelle Cotterchio14, David Duggan15, Jane C Figueiredo12, Charles S Fuchs16, Edward L Giovannucci17, Jian Gong3, Robert W Haile12, Tabitha A Harrison3, Richard B Hayes18, Michael Hoffmeister10, John L Hopper19, Thomas J Hudson20, Mark A Jenkins19, Shuo Jiao3, Noralane M Lindor21, Mathieu Lemire22, Loic Le Marchand23, Polly A Newcomb3, Shuji Ogino24, Bethann M Pflugeisen3, John D Potter25, Conghui Qu3, Stephanie A Rosse3, Anja Rudolph13, Robert E Schoen26, Fredrick R Schumacher12, Daniela Seminara2, Martha L Slattery27, Stephen N Thibodeau28, Fridtjof Thomas29, Mark Thornquist3, Greg S Warnick3, Brent W Zanke30, W James Gauderman12, Ulrike Peters6, Li Hsu31, Andrew T Chan32.   

Abstract

IMPORTANCE: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer.
OBJECTIVE: To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent. EXPOSURES: Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors. MAIN OUTCOMES AND MEASURES: Colorectal cancer.
RESULTS: Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28% vs 38%; odds ratio [OR], 0.69 [95% CI, 0.64-0.74]; P = 6.2 × 10(-28)) compared with nonregular use. In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10(-9) for interaction). Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28% vs 38%; OR, 0.66 [95% CI, 0.61-0.70]; P = 7.7 × 10(-33)) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35% vs 29%; OR, 1.89 [95% CI, 1.27-2.81]; P = .002). In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10(-9) for interaction). Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28% vs 38%; OR, 0.66 [95% CI, 0.62-0.71]; P = 1.9 × 10(-30)) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95% CI, 0.78-1.20]; P = .76). CONCLUSIONS AND RELEVANCE: In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15. Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25781442      PMCID: PMC4382867          DOI: 10.1001/jama.2015.1815

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.

Authors:  Karen W Makar; Elizabeth M Poole; Alexa J Resler; Brenna Seufert; Karen Curtin; Sarah E Kleinstein; David Duggan; Richard J Kulmacz; Li Hsu; John Whitton; Christopher S Carlson; Christine F Rimorin; Bette J Caan; John A Baron; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2013-12       Impact factor: 2.506

2.  Characterization of gene-environment interactions for colorectal cancer susceptibility loci.

Authors:  Carolyn M Hutter; Jenny Chang-Claude; Martha L Slattery; Bethann M Pflugeisen; Yi Lin; David Duggan; Hongmei Nan; Mathieu Lemire; Jagadish Rangrej; Jane C Figueiredo; Shuo Jiao; Tabitha A Harrison; Yan Liu; Lin S Chen; Deanna L Stelling; Greg S Warnick; Michael Hoffmeister; Sébastien Küry; Charles S Fuchs; Edward Giovannucci; Aditi Hazra; Peter Kraft; David J Hunter; Steven Gallinger; Brent W Zanke; Hermann Brenner; Bernd Frank; Jing Ma; Cornelia M Ulrich; Emily White; Polly A Newcomb; Charles Kooperberg; Andrea Z LaCroix; Ross L Prentice; Rebecca D Jackson; Robert E Schoen; Stephen J Chanock; Sonja I Berndt; Richard B Hayes; Bette J Caan; John D Potter; Li Hsu; Stéphane Bézieau; Andrew T Chan; Thomas J Hudson; Ulrike Peters
Journal:  Cancer Res       Date:  2012-02-24       Impact factor: 12.701

Review 3.  Meta-analysis methods for genome-wide association studies and beyond.

Authors:  Evangelos Evangelou; John P A Ioannidis
Journal:  Nat Rev Genet       Date:  2013-05-09       Impact factor: 53.242

4.  Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations.

Authors:  Hongmei Nan; Teppei Morikawa; Miia Suuriniemi; Yu Imamura; Lillian Werner; Aya Kuchiba; Mai Yamauchi; David J Hunter; Peter Kraft; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino; Matthew L Freedman; Andrew T Chan
Journal:  J Natl Cancer Inst       Date:  2013-12-07       Impact factor: 13.506

5.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

6.  IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry.

Authors:  Brenna L Seufert; Elizabeth M Poole; John Whitton; Liren Xiao; Karen W Makar; Peter T Campbell; Richard J Kulmacz; John A Baron; Polly A Newcomb; Martha L Slattery; John D Potter; Cornelia M Ulrich
Journal:  Carcinogenesis       Date:  2012-09-22       Impact factor: 4.944

7.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Authors:  Enric Domingo; David N Church; Oliver Sieber; Rajarajan Ramamoorthy; Yoko Yanagisawa; Elaine Johnstone; Brian Davidson; David J Kerr; Ian P M Tomlinson; Rachel Midgley
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

Review 8.  Comprehensive literature review and statistical considerations for GWAS meta-analysis.

Authors:  Ferdouse Begum; Debashis Ghosh; George C Tseng; Eleanor Feingold
Journal:  Nucleic Acids Res       Date:  2012-01-12       Impact factor: 16.971

9.  Functional and topological characteristics of mammalian regulatory domains.

Authors:  Orsolya Symmons; Veli Vural Uslu; Taro Tsujimura; Sandra Ruf; Sonya Nassari; Wibke Schwarzer; Laurence Ettwiller; François Spitz
Journal:  Genome Res       Date:  2014-01-07       Impact factor: 9.043

10.  Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.

Authors:  Celeste Leigh Pearce; Mary Anne Rossing; Alice W Lee; Roberta B Ness; Penelope M Webb; Georgia Chenevix-Trench; Susan M Jordan; Douglas A Stram; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Galina Lurie; Pamela J Thompson; Michael E Carney; Marc T Goodman; Kirsten Moysich; Estrid Hogdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Rachel Palmieri Weber; Argyrios Ziogas; Hoda Anton-Culver; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Louise Brinton; Nicolas Wentzensen; Jolanta Lissowska; Montserrat Garcia-Closas; Leon F A G Massuger; Lambertus A L M Kiemeney; Anne M Van Altena; Katja K H Aben; Andrew Berchuck; Jennifer A Doherty; Edwin Iversen; Valerie McGuire; Patricia G Moorman; Paul Pharoah; Malcolm C Pike; Harvey Risch; Weiva Sieh; Daniel O Stram; Kathryn L Terry; Alice Whittemore; Anna H Wu; Joellen M Schildkraut; Susanne K Kjaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

View more
  72 in total

Review 1.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

2.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

3.  Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.

Authors:  Timothy J Zumwalt; Dominik Wodarz; Natalia L Komarova; Shusuke Toden; Jacob Turner; Jacob Cardenas; John Burn; Andrew T Chan; C Richard Boland; Ajay Goel
Journal:  Cancer Prev Res (Phila)       Date:  2017-02-02

4.  Does Low Threshold Value Use Improve Proximal Neoplasia Detection by Fecal Immunochemical Test?

Authors:  Nam Hee Kim; Hyo-Joon Yang; Soo-Kyung Park; Jung Ho Park; Dong Il Park; Chong Il Sohn; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2016-04-23       Impact factor: 3.199

5.  Prevention: Tending the gut.

Authors:  Lauren Gravitz
Journal:  Nature       Date:  2015-05-14       Impact factor: 49.962

6.  Cholangiocarcinoma: from risk to prevention?

Authors:  Giovanni Brandi; Stefania De Lorenzo; Francesco Tovoli
Journal:  Transl Gastroenterol Hepatol       Date:  2016-06-24

7.  Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk.

Authors:  Xiaoliang Wang; Andrew T Chan; Martha L Slattery; Jenny Chang-Claude; John D Potter; Steven Gallinger; Bette Caan; Johanna W Lampe; Polly A Newcomb; Niha Zubair; Li Hsu; Robert E Schoen; Michael Hoffmeister; Hermann Brenner; Loic Le Marchand; Ulrike Peters; Emily White
Journal:  Cancer Res       Date:  2018-06-19       Impact factor: 12.701

Review 8.  The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer.

Authors:  Amikar Sehdev; Bert H O'Neil
Journal:  Curr Treat Options Oncol       Date:  2015-09

Review 9.  Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.

Authors:  Tsuyoshi Hamada; NaNa Keum; Reiko Nishihara; Shuji Ogino
Journal:  J Gastroenterol       Date:  2016-10-13       Impact factor: 7.527

Review 10.  Colorectal Cancer Epidemiology in the Nurses' Health Study.

Authors:  Dong Hoon Lee; NaNa Keum; Edward L Giovannucci
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.